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Abstract
Background: The BRM and BRG1 tumor suppressor genes are mutually exclusive ATPase subunits of the SWI/SNF
chromatin remodeling complex. The human adrenal carcinoma SW13 cell line can switch between a subtype which
expresses these subunits, SW13+, and one that expresses neither subunit, SW13-. Loss of BRM expression occurs
post-transcriptionally and can be restored via histone deacetylase (HDAC) inhibition. However, most previously used
HDAC inhibitors are toxic and broad-spectrum, providing little insight into the mechanism of the switch between
subtypes. In this work, we explore the mechanisms of HDAC inhibition in promoting subtype switching and further
characterize the oncogenic potential of the two epigenetically distinct SW13 subtypes.
Methods: SW13 subtype morphology, chemotaxis, growth rates, and gene expression were assessed by standard
immunofluorescence, transwell, growth, and qPCR assays. Metastatic potential was measured by
anchorage-independent growth and MMP activity. The efficacy of HDAC inhibitors in inducing subtype switching
was determined by immunofluorescence and qPCR. Histone modifications were assessed by western blot.
Results: Treatment of SW13- cells with HDAC1 inhibitors most effectively promotes re-expression of BRM and VIM,
characteristic of the SW13+ phenotype. During treatment, hyperacetylation of histone residues and
hypertrimethylation of H3K4 is pronounced. Furthermore, histone modification enzymes, including HDACs and
KDM5C, are differentially expressed during treatment but several features of this differential expression pattern
differs from that seen in the SW13- and SW13+ subtypes. As the SW13- subtype is more proliferative while the
SW13+ subtype is more metastatic, treatment with HDACi increases the metastatic potential of SW13 cells while
restoring expression of the BRM tumor suppressor.
Conclusions: When compared to the SW13- subtype, SW13+ cells have restored BRM expression, increased
metastatic capacity, and significantly different expression of a variety of chromatin remodeling factors including
those involved with histone acetylation and methylation. These data are consistent with a multistep mechanism of
SW13- to SW13+ conversion and subtype stabilization: histone hypermodification results in the altered expression
of chromatin remodeling factors and chromatin epigenetic enzymes and the re-expression of BRM which results in
restoration of SWI/SNF complex function and leads to changes in chromatin structure and gene expression that
stabilize the SW13+ phenotype.
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Background
The human adrenal cortical adenocarcinoma SW13 cell
line exists in two subtypes, originally distinguished by ex-
pression of the intermediate filament protein vimentin [1].
Subsequently, it was shown that the more abundant
SW13- subtype, in addition to lacking vimentin, does not
express either BRM (SMARCA2) or BRG1 (SMARCA4)
[2]. As these proteins are the mutually exclusive ATPase
subunits of the SWI/SNF chromatin remodeling complex
[3], SW13- cells are presumed to have a non-functional
SWI/SNF (or BAF) complex.
BRM and BRG1 are both well characterized tumor
suppressors. While BRM silencing in primary tumors
and in cancer cell lines is frequently epigenetic in nature,
BRG1 is frequently mutated but may also be epigeneti-
cally silenced (reviewed in [4–7]). In addition, recent
proteomic analysis has revealed that several other sub-
units of the SWI/SNF complex also function as tumor
suppressors. SNF5 (SMARCB1 or BAF47) is mutated in
100 % of malignant rhabdoid tumors [8, 9]. Overall,
components of the SWI/SNF complex are mutated in
approximately 20 % of cancers [10, 11] suggesting that
appropriate function of the entire complex is an import-
ant regulator of oncogenesis.
Switching between the SW13 subtypes was originally
characterized as spontaneous but, when they are isolated
by dilution cloning, the subtypes are stable for greater
than 20 doublings [12]. Subsequently, it was shown that
the switch from SW13- to SW13+ could be triggered
by addition of trichostatin A (TSA), a broad-spectrum
hydroxamic acid analog HDAC inhibitor, or its derivative
CHAP31 [12]. However, these data provide little insight
into the mechanism of the switch between SW13 sub-
types. Subsequent work extended the study of HDAC
inhibitors in the restoration of BRM activity but focused
on one activity of BRM: the requirement of BRM to acti-
vate transcription downstream of glucocorticoid receptor
signaling [13].
The expression of HDACs is dysregulated in many can-
cers, expression correlates with prognosis, and knockdown
of individual HDACs leads to apoptosis in a variety of
tumors (reviewed [14]). HDAC inhibitors FK228 (Romidep-
sin) and SAHA (Vorinostat) are FDA approved for the
treatment of cutaneous T cell lymphoma. Although several
other HDAC inhibitors are in clinical trials, none to date
show success in the treatment of solid tumors (reviewed in
[15, 16]). With the increased interest in HDAC inhibition
in cancer treatment, we investigated the involvement of
HDAC inhibitors in the SW13- to SW13+ subtype switch
more fully, only selecting HDAC inhibitors with defined
HDAC targets and minimal toxicity as evidenced by
progress in clinical trials. We also characterized the
oncogenic, metastatic, and epigenetic differences between
the SW13 subtypes.
The work presented here focused on characterizing
the SW13- to SW13+ subtype conversion as initiated by
HDACi by assessing the relative efficacy of a panel of
inhibitors. In order to put this epigenetically mediated
subtype switch in context, we explored the starting and
the ending point of the SW13- to SW13+ subtype switch
by addressing differences in oncogenic potential and
gene expression between the two subtypes which have
been isolated by dilution cloning. Thus, the data pre-
sented here investigates both the mechanism of the
HDACi mediated SW13- to SW13+ switch and the
epigenetic maintenance of the two stable subtypes.
Specifically, data presented here suggest that inhibitors
of HDAC1 most effectively promote re-expression of
BRM and VIM characteristic of the SW13+ phenotype
and do so in a dose-dependent manner. As the SW13-
subtype is more proliferative while the SW13+ subtype
is more metastatic, treatment with HDACi increases the
metastatic potential of SW13 cells while restoring ex-
pression of the BRM tumor suppressor. In addition to
hyperacetylation of histone residues, HDACi treatment
of SW13- cells for 24 h results in hypertrimethylation of
H3K4 and differential expression of several histone
modification enzymes including several HDAC enzymes.
However, when the expression patterns of these enzymes
in treated SW13- cells is compared to that seen in
SW13- and SW13+ subtypes isolated by dilution clon-
ing, significant differences are seen. These data suggest
that many of the changes induced by treatment of the
SW13- subtype with HDACi for 24 h are not maintained
in the stable subtypes after removal of HDACi.
This work has important implications for two levels of
cancer biology. First, the epigenetically controlled differ-
ences between subtypes in the SW13 line may shed light
on tumor heterogeneity and serve as a model system to
study therapeutic approaches in a cell line whose onco-
genic potential is controlled via epigenetic mechanisms.
Second, given the focus on HDACi in a variety of clinical
trials, the response of an adrenocortical carcinoma line
to treatment with HDACi has wider implications. The
ability of HDAC inhibitors to initiate a conversion be-
tween SW13- to SW13+ subtypes provides an oppor-
tunity to probe the epigenetically controlled conversion
which was previously characterized as “spontaneous” but




SW13 cells were obtained from American Type Culture
Collection (ATCC; CCL-105) and maintained in high glu-
cose DMEM supplemented with 10 % fetal bovine serum
and 10 U/ml penicillin/streptomycin at 37 °C in a humid-
ity controlled incubator. Pure cultures of SW13+ and
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SW13- cells were isolated by dilution cloning and
screened for vimentin expression (See Fig. 1a). All experi-
ments were performed with early passage clones and were
conducted between passages 5 and 20.
Assessment of cell growth and proliferation
Cells were seeded at 1 × 104 cells per/ml into six well
plates and counted daily using a hemocytometer and
trypan exclusion for 7 days. To assess differences in
subtype proliferation SW13+ and SW13- cells were
seeded into 8-well chamber slides at 0.5 × 104 cells/ml.
After 24 h, 10 μM Click-iT EdU reagent (ThermoFisher)
was added to each chamber and cells were allowed to
grow for another 24 h. Cells were then fixed and perme-
abilized and nuclear staining and EdU detection were
performed according to the manufacturer’s recommen-
dations. To assess the effects of HDACi treatment on
cell proliferation, SW13- cells were treated with either
0.51 μM MS-275 or 2 nM FK228 for 24 h before label-
ing with EdU. Cells were imaged using a Zeiss Axiovert
Apotome (Zeiss) with uniform exposure at each wave-
length in each experiment. NIH ImageJ software was
used to determine percent proliferation by dividing the
number of cells which stained positive for EdU by the
number of total cells per each group.
Soft agar assays
Cells were plated at 5 × 103 cells/well in a 0.4 % agarose/
1× media solution on top of a 0.5 % agarose/1× media
base layer in 6-well plates and maintained as above for
14 days replacing the media twice per week. Cells were
fixed and stained overnight with a 2 % paraformaldehyde/
0.005 % crystal violet solution and de-stained with water.
Colonies were photographed with an AlphaImager, and
colony number and size were determined using NIH
ImageJ software.
Transwell assays
SW13+ and SW13- cells were serum starved for 24 h
then plated at 1 × 105 cells/well in serum free media into
Nunc (Thermo Scientific) cell culture inserts with 8 μm
pore size polycarbonate membranes. Medium supple-
mented with 10 % fetal bovine serum was placed in the
outer reservoir for use as a chemoattractant. Cells
were incubated under standard conditions for 24 or
48 h after which the medium was removed, and the
cells were fixed and stained with 2 % paraformalde-
hyde/0.005 % crystal violet before visualization using
an Olympus microscope.
In situ zymography
Cells were plated at 1 × 104 cells/well in 8-chamber
slides and MMP activity was assessed as previously
described [17]. Briefly, DQ gel substrate (Life Technolo-
gies) was diluted to 40 μg/ml in MMP activity buffer
(100 mM NaCl, 100 mM Tris-HCl, pH 7.5, 10 mM CaCl2,
20 μM ZnCl, 0.05 % NP40) with sodium azide to a
concentration of 0.2 mM. Next, 200 μl diluted DQ gel
substrate was added to each well and incubated under
standard cell culture conditions overnight. Cells were
washed 3 times with 1× phosphate buffered saline before
fixation and DAPI staining. Total fluorescence was nor-
malized to total cell number in each well. All experiments
were performed at least in triplicate.
Quantification of subtype switching
SW13- cells were treated with 3 μg/ml Scriptaid
(Calbiochem), 3 μg/ml Nullscript (Biomol International),
Fig. 1 SW13- and SW13+ subtype characterization: differences in morphology, actin organization, vimentin expression, and VIM and BRM levels.
a Subtypes have distinct morphology, actin organization, and levels of vimentin expression. Left-hand panel: light microscopy photographs;
Middle panel: visualization of actin filaments with fluorescent phalloidin; Right-hand panel: expression of vimentin by immunofluorescence. Images
were taken using a 40× oil-immersion objective lens. b qPCR reveals VIM and BRM mRNA expression is ~ 8 -fold higher in the SW13+ cells
compared to the SW13- cells. Data are presented as mean ± SEM. *Denotes statistical difference between subtypes, p <0.05
Davis et al. BMC Cancer  (2016) 16:316 Page 3 of 13
2 μg/ml Depudecin (Enzo Life Sciences), 4 μg/ml BML
210 (Enzo Life Sciences), 1 μg/ml MS-275 (Selleckchem),
3 μg/ml MC1293 (Enzo Life Sciences), 0.6 μg/ml
MGCD0103 (Selleckchem), or 0.7 μg/ml FK228 (Selleck-
chem) for 0, 24, 48, and 72 h before fixation and screening
for vimentin expression to indicate subtype switching. NIH
ImageJ software was used to determine the ratio of vimen-
tin intensity normalized to cell number by dividing by the
DAPI intensity using images photographed with equal
exposures.
Immunofluorescence
Immunofluorescence was performed using standard
techniques. Specifically, for SW13-/SW13+ morphology
and subtype analysis, cells were fixed with 4 % parafor-
maldehyde, permeabilized with 0.2 % Triton-X, and
blocked with 1 % BSA before incubation with a 1:1000
dilution of a Cy3 conjugated anti-vimentin antibody
(Sigma) and 25 U/ml Alexafluor 488 phalloidin (Invitro-
gen). Samples were photographed using a Zeiss Axiovert
Apotome with uniform exposure at each wavelength in
each experiment. To quantify vimentin expression after
treatment with HDAC inhibitors, photographs were
taken using a 10× objective lens with a constant expos-
ure time and the ratio of vimentin to DAPI signal of ten
complete fields were averaged per experiment.
RNA isolation & quantitative real-time PCR
Cells were plated at 1 × 105 into 6-well plates, allowed to
adhere and grow for 24 h before indicated treatment
doses and times. Following treatment, total RNA was
isolated from cells using Trizol (Life Technologies) ac-
cording to the manufacturer’s instructions. Following
DNAse treatment, RNA was reverse-transcribed using
SuperScript II (Life Technologies). Real-time PCR was
performed on an ABI StepOne Plus thermocycler (Ap-
plied Biosystems) using SYBR Green Chemistry. Primer
sequences used were as follows: GAPDH – Forward: 5′-
ttgttgccatcaatgaccc-3′, Reverse: 5′-cttcccgttctcagccttg-3′;
BRM – Forward: 5′- gattgtagaagacatccattgtgg-3′, Reverse:
5′- gacatataaccttggctgtgttga-3′; VIM – Forward 5′- gctc
gtcaccttcgtgaata-3′, Reverse 5′- tcgttgataacctgtccatctc-3′.
Relative mRNA expression was determined using the
2-ΔΔCt method with GAPDH as the invariant control.
Pathway-focused PCR arrays
For the pathway-focused PCR arrays, cDNA synthesis was
performed using 0.5 μg total RNA and SABiosciences RT2
First Strand cDNA kit according to the kit instructions.
Profiler PCR Array System by SABiosciences following
the manufacturer’s instructions. Quantitative real-time
PCR was done using the Human Epigenetic Chromatin
Remodeling Factors RT2 Profiler PCR Array (Cat. no.
PAHS-086ZC-2) and Human Epigenetic Chromatin
Modification Enzymes RT2 Profiler PCR Array (Cat.
no. PAHS-085ZC-2) according to the manufacturer’s
instructions on an ABI StepOne Plus thermocycler.
Raw CT values were analyzed using SABiosciences
RT2 Profiler PCR Data Analysis software at http://
pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php
and the dataset containing these results is in Additional
file 1. Relative quantitation for each gene was determined
by normalizing to the geometric means of five house-
keeping genes (ACTB, B2M, GAPDH, HPRT1, and
RPLP0) comparing SW13+ to SW13- cells using the
2-ΔΔCt method.
Western blotting
Cytosolic and nuclear protein fractions were isolated
using a commercially available kit (Cell Biolabs, San
Diego, CA), and histones were extracted from the
remaining nuclear pellet by 1 min sonication in a sonic-
ating water bath. Histones were separated with pre-cast
tris-tricine gels (Bio-Rad) then transferred to a PVDF
membrane for blotting. All primary acetyl histone anti-
bodies were used at a 1:500 in 4 % BSA-TBS (0.01 %
Tween-20). For analysis of SWI/SNF proteins 30 μg
nuclear protein were loaded into pre-cast 4–20 % tris-
glycine gels before being transferred to a PVDF membrane
for blotting. All SWI/SNF antibodies were from a SWI/
SNF complex antibody sampler kit (Cell Signal Technol-
ogy) and were used at 1:1000 in 5 % NFDM-TBS (0.01 %
Tween-20). All experiments and blots were performed at
least in triplicate and relative expression was quantified
using an Odyssey Infrared Imaging system and Image
Studio v. 2.0 software (LI-COR, Lincoln, NE) using total
Histone H3 protein as the invariant control.
Statistical analysis
Differences in cell growth, percent invasion, and gene
expression between SW13- and SW13+ cells were deter-
mined using a Student’s t-test. For statistical analysis of
subtype switching, intensity ratio data were calibrated
using a direct count of percentage of number of cells
expressing vimentin over the total number of cells. As
the fluorescence intensity ratio data failed the Shapiro-
Wilks test for normality, it was analyzed using the
Independent-Sample Kruskal-Wallis test to compare
means. Western blot band densitometry was normalized
to percent of total protein loaded as determined by total
Histone H3 band density and analyzed by one-way
ANOVA using SPSS software, version 19 (Chicago, IL).
All tests were conducted at the 95 % confidence interval
and presented as means ± SEM. The fraction of cells
proliferating was compared between the four cell lines
by means of z-test according to Forthofer et al. [18].
A post-hoc Bonferroni correction was applied to all
tests to account for multiple comparisons. The z-test
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was carried out using Microsoft Excel 2002 (Microsoft
Corp.). Statistical tests were two-sided and statistical
significance was assumed if p <0.05.
Results
Characterization of SW13 subtypes
SW13+ and SW13- subtypes were isolated by dilution
cloning from a sample of grade IV, primary small cell
carcinoma from adrenal cortex obtained from ATCC.
The subtypes are stable for at least 20 doublings, and all
experiments were conducted on clones with less than
20 passages [12]. As seen in Fig. 1a, although isolated
from the same tumor sample, SW13- and SW13+ sub-
types have distinct cellular morphology and actin cyto-
skeletal structures in addition to the absence or
presence of a vimentin intermediate filament network.
It is noteworthy that the SW13- cells have a cortical
actin cytoskeleton which is characteristic of epithelial
cells while the SW13+ cells appear to be more
mesenchymal-like in that they express vimentin and
organize their actin into fibers. In SW13- cells, mRNA
for both VIM and BRM were near the limit of threshold
for detection. In contrast, mRNA expression for both
VIM and BRM were approximately eight fold higher in
SW13+ cells compared to SW13- cells (Fig. 1b). These
results are in agreement with others [12, 13, 19].
With these differences characterized, we next investigated
phenotypic differences between the two subtypes as they re-
late to oncogenic potential. Proliferation rates of each sub-
type were assessed by a standard growth assay in which cells
were plated at equal densities and the number of cells was
counted daily. The SW13- cells began their exponential
growth phase between days 4 and 5 at which the difference
in cell numbers between SW13- and SW13+ cells became
significantly different (Fig. 2a). This trend continued through
the end of the experiment at day 7, wherein the SW13- cells
were continuing to increase in number rapidly while SW13
+ cell numbers only continued to increase slowly. These
data were confirmed by measuring cell proliferation (Fig. 2b,
f) in which SW13+ had significantly reduced rates of prolif-
eration. In addition to their higher growth rate, SW13- cells
also showed a significantly greater ability to form colonies
in soft agar, forming both more numerous and larger
colonies (Fig. 2b, c, and d).
Fig. 2 SW13- cells are more proliferative and have higher rates of anchorage independent growth than SW13+. SW13- and SW13+ cells were
seeded in 6-well plates at 1 × 104 cells per well and counted using a hemocytometer and trypan exclusion every 24 h for 7 days. a The growth
rate of SW13- cells is significantly higher than SW13+ cells. b SW13- cells have higher rates of proliferation as determined by the higher number
of EdU positive cells (green) per total number of cells indicated by Hoechst 33342 staining (blue). Images were taken using a 10× objective lens
and quantitated (f) using ImageJ software. c Soft agar colony formation assays revealed SW13- cells exhibit increased rates of anchorage
independent growth as indicated by (d) increased colony number and (e) increased colony size. Data are presented as mean ± SEM. *Denotes
statistical difference between subtypes, p <0.05
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The potential for metastasis in each subtype was
then assessed by migration and MMP activity assays.
Transwell migration assays indicate that the
mesenchymal-like SW13+ cells which express vimen-
tin had significantly higher numbers of cells migrating
through the pores than the SW13- cells at both 24
and 48 h (Fig. 3a and c). These data are supported by
results from scratch assays, where SW13+ cells appear
to close a scratch faster than SW13- cells (in our
hands and [20, 21]). SW13+ cells exhibited higher
levels of MMP2/9 (collagenase) activity as measured
by increased fluorescence after incubation with a
fluorescein-quenched gelatin substrate (Fig. 3b and d).
Addition of a broad-spectrum MMP peptide inhibitor
reduced the fluorescence signal in both subtypes, suggest-
ing that at least part of the increased fluorescence is spe-
cifically due to MMP activity.
Characterization of HDAC inhibitors and subtype
switching
Although it is unclear how the SW13- subtype “spon-
taneously” transforms into the SW13+ subtype, it is
well established that HDAC inhibition can induce an
SW13- to SW13+ subtype switch [12, 13, 19]. As the
efficacy of various HDAC inhibitors has not previ-
ously been investigated, we initially screened HDAC
inhibitors to focus subsequent analyses. We tested
doses based on the reported IC50 for each HDAC in-
hibitor. However, as these values are typically based
on in vitro assays on recombinant proteins and diffi-
cult to translate to cell-based assays, a broad range of
concentrations were tested. Immunofluorescence ana-
lysis of vimentin intensity, normalized for cell number
as measured by intensity of DAPI staining, was deter-
mined using SW13- cells after incubation with an
HDACi for 1, 2, or 3 days. These data are summarized in
Fig. 4a while the immunofluorescence photographs that il-
lustrate how these data were compiled are shown in
Fig. 4b. The broad-spectrum inhibitor Scriptaid was less
efficient at inducing vimentin expression than MS-275
(Entinostat), FK228 (Romidepsin), or MGCD0103 (Moceti-
nostat). These HDAC inhibitors are reported to be potent
HDAC1 inhibitors with some activity against other HDACs
[22–24] and on the basis of these data, we focused our at-
tention on HDAC1 as the most likely enzyme to be in-
volved in the SW13- to SW13+ subtype switch.
An alternate HDACi screen, focusing on the induction
of BRM mRNA after 24 h of treatment, reveals similar
Fig. 3 SW13+ cells display properties associated with increased rates of metastasis to a greater extent than do SW13- cells. a and c Transwell
migration assays indicate SW13+ cells have increased rates of chemotaxis compared to the SW13- cells at 24 and 48 h. Images were taken using
a 4× objective lens (b and d) SW13+ cells exhibited higher levels of MMP2/9 (collagenase) activity as measured by increased fluorescence after
incubation with a fluorescein-quenched gelatin substrate (DQ gelatin). Addition of a broad-spectrum MMP inhibitor reduced the fluorescence
signal in both subtypes. Images were taken using a 40× objective lens. Data are presented as mean ± SEM. *Denotes statistical difference
between subtypes, p <0.05
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trends (Fig. 4a, right hand columns). MGCD0103 and
MS-275 showed a clear dose-response effect at the two
concentrations tested. However, even at the lowest dose
tested, FK228 yielded BRM expression levels equivalent
to the highest dose of the other two inhibitors. In this
assay, Scriptaid yielded similar levels of BRM induction
as the more specific HDAC1 inhibitors.
Treatment with HDACi which are not specific for
HDAC1 were less effective in inducing the expression of
vimentin and BRM. BML-210 (reported to have the highest
affinity for HDAC3 [25, 26]), and MC1293 (reported to
bind HDAC6 and HDAC10 and to HDAC1 with lower af-
finity [26]) are minimally effective or ineffective in inducing
vimentin expression. Depudecin treatment led to minimal
expression of vimentin and BRM but this HDAC inhibitor
has only been tested against recombinant HDAC1 [27] so
that its specificity has not been determined. TMP269 (re-
ported to be a Class IIA HDAC inhibitor specific for
HDACs 4, 5, 7, and 9 [28]), RGFP966 (an HDACi reported
to be specific for HDAC3 [29]), and HDAC6i (characterized
as an HDAC6 specific inhibitor [30]) were also tested. Al-
though some of these yielded statistically significant
Fig. 4 The ability of selected HDAC inhibitors to induce the switching from the SW13- to the SW13+ subtype. a Induction of vimentin expression was
assayed at 24, 48, and 72 h using fluorescence intensity of vimentin normalized to DAPI staining at each time point (left columns). Dose response was
measured by fold induction in BRM mRNA using qPCR for two doses of each inhibitor (right columns). b Representative immunofluorescence images
which illustrate the range of vimentin induction in panel (a). Scale ranges from no detectable vimentin immunofluorescence signal (−) to
+ representing <20 %, ++ representing 20–40 %, +++ representing 41–60 %, ++++ representing 61–80 %, and +++++ representing 81–100 % of
maximum vimentin normalized to DAPI staining. Images were taken using a 10× objective lens. Data (right hand column of panel a) are presented
as mean ± SEM
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increases in BRM at one or both tested doses, the fold in-
creases were 1–2 orders of magnitude lower than the
HDAC inhibitors which have been reported to be more
specific towards HDAC1.
We next followed the change in BRM and VIM
expression over time with the three most effective HDAC
inhibitors. These data integrate the vimentin protein data
over time (Fig. 4a, b) with the BRM expression data at a
single time point with multiple doses of HDACi.
MGCD0103, MS-275 and FK228 yielded similar results
for VIM expression (Fig. 5b). However, FK228 treatment
at 1nM yielded significantly higher increases in BRM ex-
pression (Fig. 5a). Taken together, these results strongly
suggest that inhibition of HDAC1 results in the most ef-
fective re-expression of BRM and VIM.
Differing efficacy of FK228 and MS-275 promoting
subtype switching
As shown in Fig. 5, FK228 is more effective at inducing
BRM protein expression than either of the other
HDAC1-specific inhibitors. To investigate this difference
further, we compared the efficacy of FK228 and MS-275
after 24 h of treatment with respect to proliferation,
vimentin expression, and induction of BRM protein
(Fig. 6). At this time point, FK228 reduced proliferation
to ~8 % of that seen in untreated SW13+ with significant
vimentin and BRM expression. In contrast, treatment with
MS-275 did not significantly alter proliferation and re-
sulted in less vimentin and BRM expression. Neither
HDACi treatment appears to significantly alter expression
of the four other subunits of the SWI/SNF complex which
were examined.
HDACi induced changes & comparison to SW13 subtypes
Although transient HDAC inhibition initiates the switch
from SW13- to SW13+ subtypes, the resulting epigenetic
switch between subtypes is stable for greater than 20
doublings [12]. Therefore, we hypothesized that HDAC
inhibition initiated changes in SW13- chromatin structure
and gene expression which then lead to the propagation
of a stable SW13+ subtype after the removal of the
HDACi. To probe these changes, we next addressed
Fig. 5 Inhibitors of HDAC1 increase BRM and VIM expression in a time-dependent manner. Total RNA was isolated from untreated SW13- cells
(0 h), and SW13- cells treated with 0.15 μM MGCD0103, 0.51 μM MS-275, or 2 nM FK228 for 24, 48, and 72 h. Fold change in (a) BRM and (b) VIM
mRNA expression from 0 h was determined by real-time PCR analysis using the 2-ΔΔCt method normalized to GAPDH. Data are presented
as mean ± SEM. Superscripts indicate statistical significance, p <0.05. Treatments that share the same superscripts are not significantly dif-
ferent from one another
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histone modification and differential gene expression dur-
ing HDAC treatment and in the stable subtypes.
We assayed the effects of HDACi treatment on major
modified histone lysine residues on H2B, H3, and H4.
As we hypothesize that the SW13- to SW13+ subtype
switch involves induction of gene expression, we also
included tri-methylation of H3K4 as this is strongly
associated with gene activation. Although HDACs have
many non-histone targets, we focused on histone modi-
fications associated with gene activation as the subtype
switch involves changes in gene expression. As shown
in Fig. 7, western blot analysis of purified histones
revealed that treatment with FK228 and MS-275 both
result in very elevated levels of all histone modifications
tested. Although HDACi treatment initiates the switch,
SW13+ cells do not have globally higher levels of
acetylation than SW13-.
Characterization of epigenetic regulators in SW13
subtypes
It is clear that HDACi treatment yields changes in gene
expression during the first 24 h of treatment (e.g. BRM
and VIM in Figs. 4 and 5) which are characteristic of
SW13+ cells isolated by limiting dilution cloning. We
Fig. 6 HDAC1 inhibitors reduce cell proliferation and promote restoration of VIM and BRM protein to varying degrees. a SW13- and SW13+ cells
as well as SW13- cells treated with either 0.51 μM MS-275 or 2 nM FK228 for 24 h were labeled with EdU for 24 h to determine proliferation rates.
b Representative images of two independent experiments performed in triplicate are shown. c Nuclear protein was isolated from SW13- and
SW13+ cells, as well as from SW13- cells which had been treated with either 0.51 μM MS-275 or 2 nM FK228 for 24 h and the expression of SWI/
SNF protein components were examined by western blot. Total histone H3 was used as a loading control. Data are presented as mean ± SEM.
Superscripts indicate statistical significance, p <0.05
Fig. 7 Histone acetylation in stable SW13- and SW13+ subtypes and following treatment with the HDAC inhibitors MS-275 and FK228. Pure his-
tones were isolated from SW13- and SW13+ cells, as well as from SW13- cells which had been treated with either 0.51 μM MS-275 or 2 nM FK228
for 24 h. Histones were separated on tris-tricine gels and transferred to a PVDF membrane for blotting and assessment of histone modifications.
Total histone H3 was used as a loading control. Data are presented as mean ± SEM. Superscripts indicate statistical significance, p <0.05. Within a
given row cell types that share the same superscripts are not significantly different from one another
Davis et al. BMC Cancer  (2016) 16:316 Page 9 of 13
hypothesized that other genes must be differentially
expressed during this period which alters chromatin
structure in order to generate the observed stable
subtypes after removal of HDACi. In an effort to un-
cover factors that may contribute to the maintenance of
phenotypic differences between the two subtypes, we
screened mRNA isolated from the stable SW13- and
SW13+ subtypes for differential expression of genes
involved in chromatin modification and remodeling
using pathway-focused qRT-PCR arrays (see Additional
file 1). Differential expression of six of these genes was
validated by qPCR (Fig. 8).
The differentially expressed genes appear to be in-
volved in multiple levels of epigenetic regulation. We
saw an increased expression of genes involved in histone
acetylation, like HDAC7, 9, 10, or in the binding of
acetyl-histones, such as BRD2. Additionally, the methyl
CpG DNA binding protein MDB2 is downregulated
approximately two-fold although we did not detect any
differences in global levels of DNA methylation (data
not shown). KDM5C, specific for the demethylation of
H3K4me2 and H3K4me3, showed increased expression.
We next asked if these genes were differentially expressed
in the same manner during HDACi treatment. As shown
in Fig. 8, the expression pattern during treatment showed
differences during treatment when compared to either
subtype. These data suggest subtype determination is
controlled at multiple levels and that epigenetic factors
not involved in the subtype switch may be involved in the
maintenance of stable subtype phenotype.
Discussion
Epigenetically plastic cancer cells represent a major obs-
tacle for effective treatment regimes. The ability of distinct
SW13 subtypes to transition between two subtypes with
differing oncogenic properties represents an opportunity
to explore mechanisms of epigenetic regulation. The tran-
sition from the SW13- subtype with higher rates of prolif-
eration and colony formation to the more metastatic
SW13+ is initiated by HDAC inhibition but also involves
differential expression of chromatin remodeling enzymes
and factors which read these chromatin marks, implicat-
ing multiple levels of epigenetic regulation.
Distinct SW13 subtypes which differ in BRM and
vimentin expression have been previously described
[1, 12] but have been further characterized in this
work. We found that BRM deficient SW13- cells have
a significantly higher growth rate than SW13+ cells,
which is in agreement with the findings of others
who have reported that ex vivo cultures of embryonic
fibroblasts from BRM knockout mice also grow sig-
nificantly faster than their wild-type controls [31].
Similar to the growth rate findings, the colony forming
capacity of BRM deficient SW13- cells was also signifi-
cantly higher than that of BRM expressing SW13+ cells,
but based on the vast differences in growth rates we could
not determine if this was simply due to the differences in
overall cell numbers. However, similar observations have
been noted in SW13- cells that were virally transfected to
overexpress BRM, which also had significantly reduced
anchorage independent growth [19].
While inducing expression of BRM to slow cell growth
might be considered desirable, increased expression of
vimentin is associated with a more motile and invasive
mesenchymal-like cancer cell phenotype [32]. Here, we
demonstrate that the vimentin expressing SW13+ cells
had significantly higher invasive capacity than the
SW13- cells. We also show that this is likely due to
Fig. 8 Validation of select genes related to epigenetic chromatin modification and remodeling by qPCR. Relative expression of a total of
bromodomain containing 2 (BRD2), HDAC7, HDAC9, HDAC10, lysine (K)-specific demethylase 5c (KDM5C), and methyl-CpG binding domain
protein 2 (MBD2) was examined in stable SW13- and SW13+ subtypes and SW13- cells which had been treated for 24 h with either 0.51 μM
MS-275 or 2 nM FK228. Fold-regulation was determined by the 2-ΔΔCT method using GAPDH as the invariant control. Data are presented as
mean ± SEM. *Denotes statistical difference from SW13-, p <0.05
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increased MMP expression and activity, as SW13+ cells
displayed higher amounts of collagenase breakdown, but
treatment with an MMP inhibitor decreased this activity.
As SW13+ cells also express two markers associated with
cancer stem cells (CD44 and cMET [12]), they may have
additional attributes which contribute to oncogenesis.
The inhibitor data presented here suggests a role for
inhibition of HDAC1 in promoting the conversion of
SW13- to SW13+ cells. However, given the complex role
of HDACs within the cell, it is unclear how HDAC1 may
trigger the subtype switch. First, HDACs have many
non-histone targets [33–35] and HDAC inhibitors are
likely to increase lysine acetylation on many other cellu-
lar proteins. Second, HDACs form multiple complexes
with other proteins including other HDACs so it is
unclear how HDAC inhibitors might affect the activity
of other proteins in the complex (reviewed in [14]).
Third, specificities of HDACs are typically tested using
recombinant human HDAC protein and a general HDAC
peptide substrate. It is unclear how these data translate to
in vivo activity inhibition. Fourth, although HDAC1 itself
does not appear to be differentially expressed, the expres-
sion level of several other HDACs change during the first
24 h of treatment, suggesting that alterations in acetyl-
ation as a result of HDACi treatment is complex. Despite
these factors which complicate interpretation, it is clear
that addition of inhibitors which target HDAC1 induce
the switch between SW13- and SW13+ subtypes.
Although not gene specific, the dramatic increase in
histone modifications observed after the addition of
HDAC inhibitors include those known to be deacety-
lated by HDAC1. This includes several modifications
associated with gene activation (including H3K9, H4K16
[36]) but not acetylation of H3K56, which is not associ-
ated with gene activation ([37–39] reviewed in [40, 41]).
In addition, others have seen that inhibition of histone
deacetylases alter histone methylation levels [42].
Although modification of histone acetylation and
methylation induce subtype switching, other factors may
be responsible for maintaining the subtypes. It is pos-
sible that differentially expressed chromatin remodeling
factors and epigenetic chromatin modification enzymes,
related to several of the histone modifications, may be
responsible for maintaining the SW13+ subtype for >20
generations. As suggested by Fig. 8, these maintenance
factors may be different from those involved in the
HDACi-mediated switch. As SW13+ cells isolated by
dilution cloning and SW13- cells after the removal of
HDACi appear indistinguishable, the significance of
the differential gene expression during HDACi treatment
is unclear.
Thus, the switch between the SW13 subtypes is likely
to involve both chromatin remodeling and histone modi-
fication, two important mechanisms by which chromatin
structure and gene activation are regulated. After restor-
ation of BRM expression, SW13+ cells have a functional
SWI/SNF complex [13]. The SWI/SNF complex has
been shown to both reposition and slide nucleosomes
[43, 44] and interact with modified histones [45–47],
activities predominately associated with gene activation.
However, the SWI/SNF complex, in association with
other complexes has also been associated with gene
repression [48–50]. In the case of glucocorticoid recep-
tor signaling to recruit the SWI/SNF chromatin remod-
eling complex, active BRM [13] or BRG1 [51–53] is
required and SWI/SNF recruitment results in both gene
activation and silencing [51]. This has led to models in
which transcription factors recruit chromatin remodel-
ing complexes [51, 53, 54]. In addition, the SWI/SNF
complex has been linked to changes in DNA methyla-
tion affecting the expression of CD44 [55], suggesting
that others have seen similar relationships between SWI/
SNF activity, DNA modification, and changes in pheno-
typically important gene expression.
Elucidation of the subtype switch mechanism may
have profound implications for the treatment of multiple
types of cancer. Although HDAC inhibitors have been
approved for the treatment of lymphomas, they have
not proved beneficial for the treatment of solid tumors. As
shown here, HDAC inhibitors induce a metastatic pheno-
type. To date, there is no known trigger for the SW13+ to
SW13- subtype. Further characterization of the epigenetic
differences between the two subtypes and the mechanisms
governing this subtype switch are of intense interest.
Conclusions
HDAC1 inhibition most effectively induces a switch
from the more proliferative SW13- to the more meta-
static SW13+ subtype which expresses BRM and VIM.
The switch occurs in stages with BRM mRNA elevating
earlier than vimentin. The data are consistent with a
mechanism in which HDAC inhibitors initiate subtype
conversion by inducing hypermodified histone residues
and changes in gene expression mediated by a now func-
tional SWI/SNF complex, followed by subtype switch
stabilization via changes in chromatin remodeling factors
and chromatin epigenetic enzymes.
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Additional file 1: Human Epigenetic Chromatin Modification Enzymes
and Epigenetic Chromatin Remodeling Factors RT2 Profiler™ PCR array
analysis of gene expression patterns of SW13+ cells compared to
SW13- cells. The expression patterns of 84 different genes related to (a)
chromatin modification enzymes and 84 genes related to (b) chromatin
remodeling factors are shown. Fold-change values >1 indicate an
up-regulation; while fold-change values <1 indicate a down-regulation.
Fold-change values >2 are considered significant. Comments with “A”
indicate that the average cycle threshold (CT) value is relatively high
(>30) in either the control or the test sample and is reasonably low in
the other sample (<30), suggesting that the actual fold-change value is at
least as large as the calculated and reported fold-change results. Comments
with “B” indicate that the average CT value is relatively high (>30), indicating
that its relative expression level is low in both control and test
samples, and the p value for the fold-change is either unavailable or
relatively high (p >0.05). Comments with “C” indicate that the average CT value
is either not determined or greater than the defined cut-off value (CT ≥35) in
both samples, indicating that its expression was undetected, thus rendering
this fold-change result erroneous and uninterpretable. (DOCX 18 kb)
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